Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Cody Stein

Nurse Practitioner Evansville, IN Nurse Practitioner

NPI 1346745619 CMS profile 10825664

4506 1St Ave, Evansville, IN 47710

Open in the dashboard

General payments

$1,130

80 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Cody Stein of Evansville, IN is reported in the CMS Open Payments database as having received $1,130 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $47 2
2022 General $296 15
2021 General $786 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cody Stein
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Cody Stein were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Cody Stein Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $786 $135 $40–$426 $132
2022 $296 $152 $48–$470 $149
2023 $47 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Janssen Pharmaceuticals, Inc $189 15 payments
  2. AstraZeneca Pharmaceuticals LP $161 5 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $155 16 payments
  4. Novartis Pharmaceuticals Corporation $145 18 payments
  5. Abbott Laboratories $113 4 payments
  6. Pfizer Inc. $111 7 payments
  7. Amgen Inc. $41 3 payments
  8. Urovant Sciences Inc $41 2 payments
  9. ACADIA Pharmaceuticals Inc $39 2 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $37 2 payments
  11. Other $99 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $1,055 79 payments
  2. Education $75 1 payment
Products named General payments · program years 2021–2023
  1. XARELTO $189 15 payments
  2. LifeVest $155 16 payments
  3. ENTRESTO $145 18 payments
  4. BRILINTA $127 3 payments
  5. ELIQUIS $111 7 payments
  6. VYNDAQEL $95 6 payments
  7. FARXIGA $73 3 payments
  8. CARDIOMEMS $59 2 payments
  9. Repatha $41 3 payments
  10. GEMTESA $41 2 payments
  11. Other $322 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

2,101

Median for Nurse Practitioner: 389

Drug cost

$116,292

Median for Nurse Practitioner: $21,885

Branded share of claims

13.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 60 $28,970
Tradjenta Linagliptin Brand 45 $16,398
Jardiance Empagliflozin Brand 16 $10,293
Xarelto Rivaroxaban Brand 18 $10,220
Myrbetriq Mirabegron Brand 12 $5,726
Aripiprazole Generic 33 $4,703
Dexlansoprazole Dr Dexlansoprazole Brand 18 $3,336
Galantamine Hbr Generic 12 $1,744
Novofine Autocover Pen Needle, Diabetic, Safety Brand 19 $1,688
Atorvastatin Calcium Generic 103 $1,631

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$8,985

Medicare's payments for the services billed

Medicare patients

94

Average age 72

Services billed

103

53 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 37%
Chronic kidney disease 36%
Depression 34%
Heart failure 33%
Diabetes 32%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record